US20040037910A1 - Compositions of oak bark extract, related syntheic compositions and method of using same - Google Patents

Compositions of oak bark extract, related syntheic compositions and method of using same Download PDF

Info

Publication number
US20040037910A1
US20040037910A1 US10/645,411 US64541103A US2004037910A1 US 20040037910 A1 US20040037910 A1 US 20040037910A1 US 64541103 A US64541103 A US 64541103A US 2004037910 A1 US2004037910 A1 US 2004037910A1
Authority
US
United States
Prior art keywords
ions
parts
oak bark
therapeutic composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/645,411
Inventor
David Hon
R. Stanley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/947,055 external-priority patent/US6149947A/en
Application filed by Individual filed Critical Individual
Priority to US10/645,411 priority Critical patent/US20040037910A1/en
Publication of US20040037910A1 publication Critical patent/US20040037910A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/49Fagaceae (Beech family), e.g. oak or chestnut
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof

Definitions

  • the composition may include a pharmaceutically acceptable carrier such as a water or an ointment or cream base which will result in a therapeutic composition having a pH of from 4 to 7, preferably pH 4.5 to 5.5.
  • a pharmaceutically acceptable carrier such as a water or an ointment or cream base which will result in a therapeutic composition having a pH of from 4 to 7, preferably pH 4.5 to 5.5.

Abstract

Higher concentrations of oak bark ash extract, i.e., greater than 20% by weight, are useful for the treatment of skin cancers. Lower concentrations of oak bark extract possess additional therapeutic properties not heretofore recognized. For example, preparations containing 40-80% oak bark extract are useful in the treatment of acute cancerous skin ulcers. In addition, synthetic mixtures containing potassium ions, zinc ions, calcium ions provide many of the same advantageous properties of oak bark extract. The inclusion of rubidium ions and sulfur is also advantageous for some applications.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of prior application Ser. No. 08/947,055 filed Oct. 8, 1997, which issued on U.S. Pat. No. 6,149,947 on Nov. 21, 2000. This application claims the benefit of priority, through copendency of prior application Ser. No. 07/973,071 filed Nov. 6, 1992; The status of which is now abandoned.[0001]
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • Not Applicable [0002]
  • BACKGROUND OF THE INVENTION
  • This application relates to the composition of aqueous oak bark extract, to synthetic compositions containing the key active ingredients of oak bark extract and to the use of such compositions in the treatment of skin cancer and other skin disorders. [0003]
  • Oak bark extract has been described in U.S. Pat. No. 5,080,900 which is incorporated herein by reference, for use in the treatment of skin ulcers, particularly decubitus ulcers or bed sores. This material in a base of Whitfield's ointment has also been sold under the trade name Bencelok® for use in the treatment of minor skin irritations. The amount of oak bark extract in these materials was relatively low, however. For example, the Bencelok® preparations have contained from 0.25 to 3% by weight of ash-derived components based upon the total weight of the preparation. [0004]
  • BRIEF SUMMARY OF THE INVENTION
  • It has now been found that higher concentrations of oak bark extract possess highly useful properties for the treatment of skin cancers, and that lower concentrations of oak bark extract possess additional therapeutic properties not heretofore recognized. For example, preparations containing 40-80% oak bark extract are useful in the treatment of acute cancerous skin ulcers. In addition, it has now been found that synthetic mixtures containing potassium ions, zinc ions, calcium ions provide many of the same advantageous properties of oak bark extract. The inclusion of rubidium ions and sulfate ions is also advantageous for some applications. [0005]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Oak bark extract for use in the present invention is prepared from oak bark ash. The bark utilized can be from Red Oak ([0006] Ouercus rupra L), Black Oak (Quercus Velutina Lam.). Shumerd Oak (Quercus shumardi i Buckl.), Scarlet Oak (Quercus coccinea Muenchb.), Willow Oak (Quercus phellos L.) and other species of the Erythrobalanus group. The oak bark is burned to convert it into an ash, which is cooled and screened to provide a powder.
    TABLE 1
    Solution (%) Temperature (° C.) Processing Time (hours)
    0.25 98 ± 2 1.00
    1.00 98 ± 2 2.00
    10.00 98 ± 2 8.00
    20.50 98 ± 2 12.00
    40.00 98 ± 2 18.00
    80.00 98 ± 2 21.00
  • The ash powder is then poured slowly into boiling water and boiled, with stirring, for a period of time (1.5 to 4 hours) to achieve an intermediate oak bark extract. The hot intermediate extract is then filtered to recover a clear filtrate and boiled for an additional period of time to achieve the desired final concentration of oak bark extract. During this boiling step, a white precipitate forms which is separated from the oak bark extract and discarded. Table 1 shows processing conditions which can be used to prepare oak bark extract of various final Concentrations. The solution concentrations are expressed as weight percent of oak bark ash derived material. [0007]
  • The oak bark extracts in accordance with the invention are complex mixtures of inorganic materials. Further, as is evident from the results of elemental analysis on the various solutions, (See Table 2) the relative amounts of the constituents vary from one concentration to another. For example, the 40% solutions (i.e., a solution containing a total of 40% by weight of extracted oak bark materials and 60% by weight water) was found to be highly enriched in rubidium relative to lower concentration solutions. [0008]
  • The therapeutic activity of various constituents of oak bark extract has been analyzed with the result that silicon, strontium, barium, manganese, gallium, zirconium and titanium appear to be unnecessary, while therapeutic efficacy has been found for compositions containing just potassium, zinc and calcium ions, in combination with suitable counterions. Thus, synthetic formulations containing, by weight of inorganic solids, 10 to 80 parts potassium ions, preferably 30 to 50 parts 0.00001 to 20 parts zinc ions, preferably 1 to 10 parts 0.01 to 10 parts calcium ions, preferably 1 to 5 parts 0 to 40 parts rubidium ions, preferably 1 to 30 parts, and 0 to 5 parts sulfur, in the form of elemental sulfur or sulfate, together with pharmaceutically acceptable counterions (e.g., C[0009] L, SO4, CO3, OH, Br). The solution may also contain other inorganic cations, for example, up to 10 parts by weight of inorganic solids of cobalt, copper, iron, manganese, nickel, strontium or aluminum ions, preferably up to 1 part by weight. Further, the composition may include a pharmaceutically acceptable carrier such a water or an ointment or cream base which will result in a therapeutic composition having a pH of from 4 to 7, preferably pH 4.5 to 5.5.
    TABLE 2
    CONCENTRATION OF OAK BARK EXTRACT
    ELEMENT 0.25% 1.00% 10.00% 20.50% 40.00%
    Hydrogen 13.77% 12.07% 12.15% 11.00% 10.11%
    Oxygen 86.22% 87.91% 85.55% 84.40% 64.45%
    Potassium 43541 ppm 0.01% 2.10% 4.50% 25.15%
    Bromine 0.05 ppm 0.07 ppm 2.00 ppm 2.02 ppm 2.02 ppm
    Calcium 13.43 ppm 35.67 ppm 99.45 ppm 208.72 ppm 1000.43 ppm
    Chlorine 24.87 ppm 45.11 ppm 92.50 ppm 185.31 ppm 235.2 ppm
    Chromium 0.23 ppm 0.55 ppm 1.01 ppm 0.49 ppm 1000.12 ppm
    Cobalt ND ND 0.08 ppm 0.16 ppm 0.29 ppm
    Copper ND ND 0.11 ppm 0.33 ppm 0.68 ppm
    Iron ND ND 0.85 ppm 1.70 ppm 2.12 ppm
    Lead ND ND 0.23 ppm 0.56 ppm 0.3 ppm
    Manganese ND ND 0.04 ppm 0.07 ppm 0.07 ppm
    Nickel ND ND 0.33 ppm 0.66 ppm 2.11 ppm
    Rubidium 17.25 ppm 42.79 ppm 110.13 ppm 220.60 ppm 1320.23 ppm
    Strontium ND 0.01 ppm 1.79 ppm 2.99 ppm 3.3 ppm
    Sulfur 5.45 ppm 30.01 ppm 180.01 ppm 373.40 ppm 421.3 ppm
    Titanium 0.81 ppm 0.24 ppm 1.79 ppm 3.44 ppm 0.1 ppm
    Zinc 1.74 ppm 4.78 ppm 8.81 ppm 17.65 ppm 12.3 ppm
  • Oak bark extract or the synthetic mixtures of the invention have been found to provide a variety of beneficial therapeutic properties. The therapeutic applications and the concentration of oak bark extract or synthetic mixture by weight of solids are summarized in Table 3. [0010]
    TABLE 3
    Weight % of
    Oak Bark Extract Indicati ns
    0.25% Fungal, infection, minor infection, insect
    bites
    1.00% Eczema, minor burns, sunburn, poison
    oak, poison ivy, poison sumac, wound
    healing
    3.00% Pyordermas, dermatitis, pruritic
    dermatoses, eczema, minor burns,
    sunburn, poison oak, poison ivy, poison
    sumac, decubitis ulcers, tropical ulcers,
    wound healing
    5.00% Decubitis, psoriasis
    10.00% Psoriasis, impetigo, Kaposi sarcoma,
    warts, gangrene, ischemic ulcer,
    keratosis
    20.50% Precancerous lesions, basal cell
    epithelioma, squamous cell carcinoma,
    keratoacanthoma
    40.00% Acute Cancerous ulcers
    80.00% Acute Cancerous ulcers
  • In particular, compositions containing about 20% or more, preferably 30% to 80% and more preferably 40% to 80%, of oak bark extract or a similarly concentrated synthetic mixture according to the invention can be used to treat cancerous and precancerous skin lesions. As used herein, the tern cancerous and precancerous skin lesions includes but is not limited to basal cell epithelioma, squamous cell carcinoma, keratoacanthoma. [0011]
  • Compositions according to the invention are also useful for treating abrasions and other partial thickness wounds. Useful compositions include at least potassium, zinc and calcium ions and may include other ionic components as well as described in Examples 1 and 2. The composition is advantageously applied in a cream or ointment base over a period of several days. Similar compositions were found to be useful in the treatment of gangrene, impetigo, psoriasis, although longer periods of treatment may be required. [0012]
  • While not intending to be bound by any particular mechanism of action, it appears that oak bark extract and synthetic mixtures containing the key ingredients of oak bark extract function to enhance wound healing by providing complexing ions which interact with enzymes such as alkaline phosphatase, carbonic anhydrase, carboxypeptidase, various enhydrogenases, arginase, carnosinase, dehydropeptidase, glycine dipeptidase, histidine deaminase and tripeptidase, oxyloacetic carboxylase and some lecithinases and enolases. These enzymes are involved in numerous biosynthetic pathways necessary for wound healing, for example, collagen biosynthesis, and are believed to function with greater efficiency in the presence of the complexing ions.[0013]
  • EXAMPLE 1
  • A synthetic mixture was prepared by combining potassium sulfate (7.50 g), potassium hydroxide (7.65 g), calcium hydroxide (0.05 g), iron sulfate (0.4 mg), Cobaltous bromide (0.1 mg), copper chloride (0.3 mg), zinc sulfate (1.2 mg) strontium chloride (0.3 mg) and rubidium sulfate (0.13 mg) in distilled water (59.09 g) and Whitfield's ointment (433.57 g). The total amount of synthetic chemicals was 3% in weight. The ointment was applied twice daily to three patients with severe abrasions. Prior to treatment, abrasions were cleaned with rubbing alcohol. All patients showed disappearance of abrasion within five days of treatments. [0014]
  • EXAMPLE 2
  • A synthetic mixture was prepared by combining zinc oxide (2.5 g), calcium hydroxide (2 g), potassium carbonate (3.5 g) and potassium hydroxide (12 g) in distilled water (80 g) and Whitfield's ointment (57 g). The total amount of synthetic chemicals was 3% in weight. This formulation was used to treat an outpatient with a severe abrasion on his left arm. The abrasion was cleaned with rubbing alcohol to remove any contamination. The ointment was applied to abrasion twice daily. The abrasion healed within 72 hours. [0015]
  • EXAMPLE 3
  • A synthetic mixture was prepared by combining zinc sulfate (2.5 g), calcium hydroxide (2 g), potassium carbonate (3.5 g) and potassium hydroxide (12 g) in distilled water (80 g) and Whitfield's ointment (57 g). The total amount of synthetic chemicals was 3% in weight. This formulation was used to treat an outpatient with venous stasis. The venous stasis was cleaned with a 3% solution of hydrogen peroxide, and pad dried. The ointment was applied to venous stasis twice daily. Reduction in ulcer size 60-70% within 72 hours was observed. Complete granulation within 5 days for ulcers less than 2 cm; 7 days for ulcers less than 4 cm. [0016]
  • EXAMPLE 4
  • A synthetic mixture was prepared by combining zinc sulfate (2.5 g), calcium hydroxide (2 g) potassium carbonate (3.5 g) and rubidium hydroxide (6 g), potassium hydroxide (6 g) in distilled water (80 g) and Whitfield's ointment (57 g). The total amount of synthetic chemicals was 3% in weight. This formulation was used to treat an outpatient with laceration. The laceration was cleaned with rubbing alcohol and air dried. The ointment was applied to the laceration twice daily. The laceration reduced it's redness within 4 hours and healed within 72 hours. [0017]
  • EXAMPLE 5
  • A synthetic mixture was prepared by combining potassium hydroxide (6.6 g) rubidium hydroxide (0.4 g), zinc sulfate (0.6 g), sulfur (2 g) and calcium hydroxide (0.1 g) in distilled water (14.55 g) and Whitfield's ointment (72.75 g). The total amount of synthetic chemicals was 10% in weight. This formulation was used to treat an outpatient with psoriasis in the right arm and right leg. The psoriasis was cleaned with rubbing alcohol to remove any contamination. The ointment was applied to abrasion twice daily. The psoriasis healed in six weeks. [0018]
  • EXAMPLE 6
  • A synthetic mixture was prepared by combining potassium hydroxide (6.6 g), rubidium hydroxide (0.4 g), zinc sulfate (0.6 g), sulfur (2 g) and calcium hydroxide (0.1 g) in distilled water (14.55 g) and. Whitfield's ointment (72.75 g). The total amount of synthetic chemicals was 10% in weight. This formulation was used to treat an outpatient with impetigo at the back. The back was thoroughly cleaned with rubbing alcohol to remove any contamination. The ointment was applied to impetigo twice daily. The impetigo healed in four weeks. [0019]
  • EXAMPLE 7
  • A synthetic mixture was prepared by combining potassium hydroxide (6.6 g), rubidium hydroxide (0.4 g), zinc sulfate (0.6 g), sulfur (2 g) and calcium hydroxide (0.1 g) in distilled water (14.55 g) and Whitfield's ointment (72.75 g). The total amount of synthetic chemicals was 10% in weight. This formulation was used to treat an outpatient with gangrene in his feet. The gangrene was thoroughly cleaned with hydrogen peroxide to remove any contamination. The ointment was applied to gangrene twice daily. The gangrene healed in six weeks. [0020]
  • EXAMPLE 8
  • A polyethylene-glycol based ointment (105 g) with 10% oak bark extract was prepared from red oak bark extract (20.5%, 100 g) to treat pustules on a patient's face and neck. The pustules were cleaned with a 3% saline solution. The ointment was then applied to the pustules. After 12 hours of treatment, the “angry red face” began to fade; after 20 hours, the face began to turn normal. The pustules never re-occurred. [0021]
  • EXAMPLE 9
  • An aqueous solution containing 80% red oak bark by weight was prepared in accordance with the conditions outlined in Table 1. The solution was used to treat a patient with melanoma in the front of his left ear. The size of the tumor was as big as a thumbnail. At the top of it was a crusty brown. The therapy included removal of the exudate by washing the lesions with soap and water and pad dried. The solution was applied twice daily to the melanoma. After two weeks of treatments, the tumor started to clear up; and after an additional two weeks of treatments, the melanoma completely disappeared, leaving only a clean, white-looking spot. [0022]
  • EXAMPLE 10
  • A polyethylene glycol-based ointment (33.33 g) with 30% oak bark extract was prepared from red oak bark extract (40.0%, 100 g) to treat venous stasis of a woman. The venous stasis was cleaned with rubbing alcohol. Air dried. The ointment was applied twice daily over a period of four days, the swelling reduced and the pain subsided. [0023]
  • EXAMPLE 11
  • Two ointments with a concentration of 20% and 50% oak bark extract solution, respectively, were prepared by mixing the 80% red oak extract solution with salicylic acid, benzoic acid and polyethylene glycol. The 20% ointment contained lOOg red oak extract solution (80%), 103.20 g PEG3350, 156.03 g PEG400, 30.57 g benzoic acid and 10.20 g salicylic acid. The 50% ointment contained 10 g red oak extract solution (80%), 20.64 g PEG3350, 31.21 g PEG400, 6.11 g benzoic acid and 2.04 g salicylic acid. The 50% ointment was applied twice daily to a patient with Kaposi's sarcoma. Prior to application, open lesions were cleaned with 3% hydrogen peroxide. A wet dressing was used. The size of the sarcoma reduced to a diameter of an inch after one week of treatment. The 20% ointment was applied thereafter. The patient completely healed in 45 days of treatments. [0024]
  • EXAMPLE 12
  • An ointment with 3% oak bark extract was prepared by mixing 20.5% oak bark extract solution with salicylic acid (19.82 g), benzoic acid (59.41 g), PEG3350 (200.55 g) and PEG400 (303.22 g). The ointment was used to treat molds of an HIV-positive patient. Ointment was applied twice daily to molds directly. Within 3 weeks, molds disappeared. [0025]
  • EXAMPLE 13
  • An ointment with 3% oak bark extract by weight was prepared, by mixing 20.5% oak bark extract solution with salicylic acid (19.82 g), benzoic acid (59.41 g), PEG3350 (200.55 g) and PEG400 (303.22 g). The ointment was used to treat molds of an HIV-positive patient. Ointment was applied twice daily to molds which were surgically clipped. The mold dried up within 48 hours. [0026]
  • EXAMPLE 14
  • A male with six Kaposi's lesions was treated with an ointment containing 100 g 8% oak bark extract solution and 156.25 g polyethylene glycol. Ointment was applied twice daily directly over lesions. Lesions with sizes larger than one inch reduced their sizes 60% after 36 days of treatments. Lesions with sizes less than one-half of an inch healed within a week of treatment. [0027]
  • EXAMPLE 15
  • A polyethylene glycol-based ointment (105 g) contained 10% oak bark extract by weight, prepared from 100 g of 20.5% red oak bark solution, was used to treat a patient suffering from actinic Keratosis. The ointment was applied twice daily over a period of four months, by which time the lesions had disappeared. [0028]
  • EXAMPLE 16
  • Five additional synthetic compositions were prepared as follows: [0029]
  • (a) Potassium carbonate (10 g), rubidium hydroxide (4 g), zinc sulfate (2.5 g), calcium hydroxide (3.5 g) distilled water (80 g), Whitfield's ointment (57 g). [0030]
  • (b) Potassium hydroxide (10 g), rubidium hydroxide (4 g), Zinc sulfate (2.5 g), calcium hydroxide (3.5 g), distilled water (80 g), Whitfield's ointment (57 g). [0031]
  • (c) Potassium carbonate (12 g), rubidium hydroxide (5.5 g), zinc oxide (2.5 g), distilled water (80 g), distilled water (80 g), Whitfield's ointment (57 g). [0032]
  • (d) potassium carbonate (12 g), rubidium hydroxide (5.5 g), zinc sulfate (2.5q) distilled water (80 g), Whitfield's ointment (57 g). [0033]
  • (e) Calcium hydroxide (12 g), rubidium hydroxide (5.5 g), zinc sulfate (2.5 g), distilled water (80 g), Whitfield's ointment (57 g) [0034]
  • Amendments to the Specification: [0035]
  • Substitute the following paragraph [0001] for paragraph [0001] of the specification as filed. [0036]
  • The above-styled application is a continuation of of prior application Ser. No. 09/716,890, filed Nov. 20. 2000, entitled: COMPOSITIONS OF OAK BARK EXTRACT RELATED SYNTHETIC COMPOSITIONS AND METHOD OF USING SAME, which is a continuation of Ser. No. 08/947,055, filed Oct. 8, 1997, now U.S. Pat. No. 6,149,947, and claims priority, through copendency, of prior application Ser. No. 07/973,071, filed Nov. 6, 1992 (now abandoned). [0037]

Claims (21)

1. A composition comprising from 40 to 80% by weight of solids of an aqueous extract of oak bark.
2. A composition comprising
10 to 80 parts potassium ions
0.00001 to 20 parts zinc ions
0.01 to 10 parts calcium ions
0 to 40 parts rubidium ions, and
0 to 5 parts sulfur, in the form of elemental sulfur or sulfate by weight of inorganic solids, optionally diluted in a pharmaceutically acceptable carrier, with the proviso that the composition is not identical to an aqueous extract of oak bark ash.
3. A composition according to claim 2, herein the carrier is water.
4. A composition according to claim 2, wherein the carrier is a crème base.
5. A method for treating cancerous and precancerous skin lesions comprising applying to the lesion an effective amount of a therapeutic composition comprising therapeutically effective amounts of potassium ions, calcium ions and zinc ions.
6. A method according to claim 5, wherein the therapeutic composition is an aqueous extract of oak bark.
7. A method according to claim 6, wherein the therapeutic composition contains at least 20% by weight of solids of oak bark extract.
8. A method according to claim 6, wherein the therapeutic composition contains at least 40% by weight of solids of oak bark extract.
9. A method according to claim 5, wherein the therapeutic composition comprises
10 to 80 parts potassium ions
0.00001 to 20 parts zinc ions
0.01 to 10 parts calcium ions
0 to 40 parts rubidium ions, and
0 to 5 parts sulfur, in the form of elemental sulfur or sulfate by weight of inorganic solids, optionally diluted in a carrier.
10. A method for treating psoriasis comprising topically applying a composition comprising an effective amount of a therapeutic composition comprising therapeutically effective amounts of potassium ions, calcium ions and zinc ions to psoriatic skin.
11. A method according to claim 10, wherein the therapeutic composition comprises an aqueous extract of oak bark.
12. A method according to claim 11, wherein the therapeutic composition contains at least 10% oak bark extract solids by weight.
13. A method according to claim 10, wherein the therapeutic composition comprises
10 to 80 parts potassium ions
0.00001 to 20 parts zinc ions
0.01 to 10 parts calcium ions
0 to 40 parts rubidium ions, and
0 to 5 parts sulfur, in the form of elemental sulfur or sulfate by weight of inorganic solids, optionally diluted in a carrier.
14. A method for treating impetigo comprising topically applying a composition comprising an effective amount of a therapeutic composition comprising therapeutically effective amounts of potassium ions, zinc ions and calcium ions to impetigos skin.
15. A method according to claim 14, wherein the therapeutic composition comprises an aqueous extract of oak bark.
16. A method according to claim 15, wherein the therapeutic composition contains at least 10% oak bark extract solids by weight.
17. A method according to claim 10, wherein the therapeutic composition comprises
10 to 80 parts potassium ions
0.00001 to 20 parts zinc ions
0.01 to 10 parts calcium ions
0 to 40 parts rubidium ions, and
0 to 5 parts sulfur, in the form of elemental B sulfur or sulfate by weight of inorganic solids, optionally diluted in a carrier.
18. A method for treating gangrene comprising topically applying a composition comprising an effective amount of a therapeutic composition comprising therapeutically effective amounts of potassium ions, calcium ions and zinc ions to gangrenous tissue.
19. A method according to claim 19 wherein the therapeutic composition comprises an aqueous extract of oak bark.
20. A method according to claim 18, herein the therapeutic composition contains at least 10% oak bark extract solids by weight.
21. A method according to claim 18, wherein the therapeutic composition comprises
10 to 80 parts potassium ions
0.00001 to 20 parts zinc ions
0.01 to 10 parts calcium ions
0 to 40 parts rubidium ions, and
0 to 5 parts sulfur, in the form of elemental sulfur or sulfate by weight of inorganic solids, optionally diluted in a carrier.
US10/645,411 1992-11-06 2003-08-21 Compositions of oak bark extract, related syntheic compositions and method of using same Abandoned US20040037910A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/645,411 US20040037910A1 (en) 1992-11-06 2003-08-21 Compositions of oak bark extract, related syntheic compositions and method of using same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97307192A 1992-11-06 1992-11-06
US33479594A 1994-11-04 1994-11-04
US59668996A 1996-02-02 1996-02-02
US08/947,055 US6149947A (en) 1992-11-06 1997-10-08 Compositions of oak bark extract related synthetic compositions and method of using same
US09/716,890 US7014870B1 (en) 1992-11-06 2000-11-20 Compositions of oak bark extract related synthetic compositions and method of using same
US10/645,411 US20040037910A1 (en) 1992-11-06 2003-08-21 Compositions of oak bark extract, related syntheic compositions and method of using same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/716,890 Continuation US7014870B1 (en) 1992-11-06 2000-11-20 Compositions of oak bark extract related synthetic compositions and method of using same

Publications (1)

Publication Number Publication Date
US20040037910A1 true US20040037910A1 (en) 2004-02-26

Family

ID=31892327

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/716,890 Expired - Fee Related US7014870B1 (en) 1992-11-06 2000-11-20 Compositions of oak bark extract related synthetic compositions and method of using same
US10/645,411 Abandoned US20040037910A1 (en) 1992-11-06 2003-08-21 Compositions of oak bark extract, related syntheic compositions and method of using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/716,890 Expired - Fee Related US7014870B1 (en) 1992-11-06 2000-11-20 Compositions of oak bark extract related synthetic compositions and method of using same

Country Status (1)

Country Link
US (2) US7014870B1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191620A1 (en) * 2006-02-03 2007-08-16 Ramirez Jose E Chemical compositions and methods of making them
US20070203354A1 (en) * 2006-02-03 2007-08-30 Ramirez Jose E Chemical Compositions and Methods of Making Them
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US20110008271A1 (en) * 2009-07-13 2011-01-13 Jr Chem, Llc Rosacea treatments using polymetal complexes
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
WO2013012968A1 (en) * 2011-07-20 2013-01-24 3M Innovative Properties Company Dressing with ion-carrying composition
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
US9427397B2 (en) 2009-01-23 2016-08-30 Obagi Medical Products, Inc. Rosacea treatments and kits for performing them
US20170202769A1 (en) * 2014-04-18 2017-07-20 Gregory P. Pilant Methods and Compositions for Topical Delivery for Skin Care

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2891548T3 (en) 2007-10-15 2022-01-28 Hs Pharmaceuticals Llc Silicate-containing compositions and treatment methods
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
US9351995B1 (en) 2011-04-29 2016-05-31 Red Oax Holdings, LLC Compositions and methods of enhancing wound healing
EP2736486B1 (en) 2011-07-28 2019-03-06 3M Innovative Properties Company Wound-healing compositions and method of use
WO2013025579A2 (en) 2011-08-17 2013-02-21 3M Innovative Properties Company Monomer-grafted fibers and uses thereof
GB201402672D0 (en) 2014-02-14 2014-04-02 Medical Res Council Materials and methods relating to stabilised polymeric silicate compositions
WO2016123539A1 (en) 2015-01-29 2016-08-04 Wardell Mark R Wound healing compositions involving medicinal honey, mineral ions, and methylglyoxal, and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080900A (en) * 1990-04-17 1992-01-14 Stanley R Thomas Treatment of skin ulcers with an aqueous extract of oak bark ash
US5458881A (en) * 1991-06-03 1995-10-17 Givaudan-Lavirotte N-acylated derivatives of mixtures of amino acids derived from hydrolysates of cereal proteins and their applications
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6149947A (en) * 1992-11-06 2000-11-21 Greystone Medical Group, Inc. Compositions of oak bark extract related synthetic compositions and method of using same
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080900A (en) * 1990-04-17 1992-01-14 Stanley R Thomas Treatment of skin ulcers with an aqueous extract of oak bark ash
US5458881A (en) * 1991-06-03 1995-10-17 Givaudan-Lavirotte N-acylated derivatives of mixtures of amino acids derived from hydrolysates of cereal proteins and their applications
US6149947A (en) * 1992-11-06 2000-11-21 Greystone Medical Group, Inc. Compositions of oak bark extract related synthetic compositions and method of using same
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178318A1 (en) * 2006-02-03 2011-07-21 Ramirez Jose E Methods of making bimetal complexes
US20070203354A1 (en) * 2006-02-03 2007-08-30 Ramirez Jose E Chemical Compositions and Methods of Making Them
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US20070191620A1 (en) * 2006-02-03 2007-08-16 Ramirez Jose E Chemical compositions and methods of making them
US8148563B2 (en) 2006-02-03 2012-04-03 Jr Chem, Llc Chemical compositions and methods of making them
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US8505730B2 (en) 2008-01-04 2013-08-13 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US9427397B2 (en) 2009-01-23 2016-08-30 Obagi Medical Products, Inc. Rosacea treatments and kits for performing them
US20110008271A1 (en) * 2009-07-13 2011-01-13 Jr Chem, Llc Rosacea treatments using polymetal complexes
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
WO2013012968A1 (en) * 2011-07-20 2013-01-24 3M Innovative Properties Company Dressing with ion-carrying composition
US20170202769A1 (en) * 2014-04-18 2017-07-20 Gregory P. Pilant Methods and Compositions for Topical Delivery for Skin Care
EP3131524A4 (en) * 2014-04-18 2018-01-03 Gregory P. Pilant Methods and compositions for topical delivery for skin care
TWI682782B (en) * 2014-04-18 2020-01-21 葛列戈里P 派倫 Methods and compositions for topical delivery for skin care
US11160745B2 (en) * 2014-04-18 2021-11-02 Gregory P. Pilant Methods and compositions for topical delivery for skin care
TWI768228B (en) * 2014-04-18 2022-06-21 葛列戈里 P 派倫 Methods and compositions for topical delivery for skin care
AU2020273346B2 (en) * 2014-04-18 2022-11-24 Gregory P. Pilant Methods and compositions for topical delivery for skin care

Also Published As

Publication number Publication date
US7014870B1 (en) 2006-03-21

Similar Documents

Publication Publication Date Title
CA2148795C (en) Compositions of oak bark extract, related synthetic compositions, and method of using same
US7014870B1 (en) Compositions of oak bark extract related synthetic compositions and method of using same
US4512978A (en) Dermatological composition useful in the treatment of psoriasis
US4512977A (en) Therapeutic selenium compositions and the use thereof
US6261574B1 (en) Cream formulation for topical application
US3943248A (en) Methods of treating burns using colophony containing preparations
CA1261757A (en) Compositions for treating acne vulgaris and methods of making and using same
WO1994009798A1 (en) Mixtures or complexes containing calcium and sulfate
US20100284951A1 (en) Novel compositions for the treatment of wounds and skin care
US20040131693A1 (en) Composition with a base of a therapeutically active compound, in particular honey, for the treatment of wounds
US20060246154A1 (en) Composition of oak bark extract, related synthetic compositions, and method of using same
CA2478137A1 (en) Metal ion chelate complexes and use thereof
US4162308A (en) Water soluble extracts of certain marine red algae and processes for use thereof
US4162309A (en) Water soluble extracts of certain marine red algae and processes for use thereof
CA1112164A (en) Therapeutic selenium compositions and the use thereof
EP0352826A2 (en) Use of 5-aminosalicylic acid in the treatment of dermatological disorders
US20040037898A1 (en) Compositions of oak bark extract, related synthetic compositions and method of using same
CA2102352A1 (en) Medicinal salve composition
US4340590A (en) Method for reducing or inhibiting ecchymosis in skin tissues with inorganic selenium compositions
KR19990078667A (en) Cream for Itching Symptoms Improvement and Manufacturing Method thereof
EP0699443B1 (en) Elder-containing skin preparation
GB2177918A (en) Pharmaceutical compositions containing procaine
KR950007046B1 (en) The beauty wash containing a crude drug and it's preparation
WO1992011020A1 (en) Improvements relating to seaweed-derived preparations
JP2766811B2 (en) Aqueous skin external preparation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION